NextFin News - Shares of Hims & Hers Health surged 9.16% on Thursday, trading near $26.00, after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. signaled a regulatory shift that could legitimize the burgeoning market for therapeutic peptides. The announcement, made late Wednesday, revealed that the Food and Drug Administration (FDA) plans to convene a Pharmacy Compounding Advisory Committee in July 2026 to review a dozen peptides for potential inclusion on the 503A bulk compounding list. This designation would allow specialized pharmacies to legally produce these substances on an individual prescription basis, providing a regulated alternative to the current "gray market" of unregulated online sellers.
The policy shift arrives at a critical juncture for Hims & Hers, which has seen its stock price fluctuate as investors weigh the long-term viability of its compounded GLP-1 weight-loss business. While the company has thrived by offering affordable, compounded versions of popular obesity drugs during periods of national shortage, the eventual resolution of those shortages threatens to force a transition toward lower-margin branded alternatives. Peptides represent a strategic pivot, offering a new category of high-margin, personalized wellness treatments that could offset potential revenue gaps in the weight-loss segment.
Michael Cherny, an analyst at Leerink Partners, characterized the FDA’s move as a positive development that provides a "clearer regulatory path" for Hims & Hers to scale its operations. Cherny, who maintains a hold-equivalent rating on the stock with a $25 price target, is known for a cautious but data-driven approach to the telehealth sector. His assessment suggests that while the policy change is a significant tailwind, it is not a guaranteed windfall. Cherny noted that the inclusion on the compounding list would not immediately translate into revenue, but rather serves as a long-term growth avenue that the company is likely to pursue aggressively.
This perspective is currently the primary lens through which the market is viewing the news, though it does not yet represent a broad Wall Street consensus. The telehealth industry remains deeply divided over the safety and efficacy of peptides, many of which lack the rigorous clinical trial data associated with traditional pharmaceuticals. Dr. Patrick Carroll, Chief Medical Officer at Hims & Hers, argued that the goal is to bring these therapies into a "physician-led" environment, yet the medical community at large remains skeptical of substances like MK-677, which is among the peptides under review and has historically been scrutinized for its use in unregulated performance-enhancing contexts.
The financial stakes are high for Hims & Hers, which laid the groundwork for this transition in February 2025 by acquiring a California-based peptide manufacturing facility. CEO Andrew Dudum has consistently framed peptide therapy as "future-facing innovation," signaling to shareholders that the company’s infrastructure is already prepared for a post-GLP-1 shortage environment. However, the regulatory process is fraught with uncertainty. The July 2026 committee meeting is merely the first step in a lengthy review, and the FDA has historically been conservative regarding the safety profiles of compounded substances.
For investors, the risk lies in the gap between regulatory approval and consumer adoption. If the FDA excludes key high-demand peptides from the bulk list, or if clinical evidence fails to materialize, the "peptide pivot" could stall. Furthermore, the company must navigate the reputational risk of marketing substances that some health experts still view as experimental. While the current administration’s openness to alternative health therapies provides a favorable backdrop, the ultimate success of Hims & Hers will depend on its ability to convert regulatory permission into a sustainable, evidence-based clinical practice.
Explore more exclusive insights at nextfin.ai.
